234 related articles for article (PubMed ID: 25365139)
1. Autoantibody signature for the serologic detection of ovarian cancer.
Anderson KS; Cramer DW; Sibani S; Wallstrom G; Wong J; Park J; Qiu J; Vitonis A; LaBaer J
J Proteome Res; 2015 Jan; 14(1):578-86. PubMed ID: 25365139
[TBL] [Abstract][Full Text] [Related]
2. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer.
Anderson KS; Sibani S; Wallstrom G; Qiu J; Mendoza EA; Raphael J; Hainsworth E; Montor WR; Wong J; Park JG; Lokko N; Logvinenko T; Ramachandran N; Godwin AK; Marks J; Engstrom P; Labaer J
J Proteome Res; 2011 Jan; 10(1):85-96. PubMed ID: 20977275
[TBL] [Abstract][Full Text] [Related]
3. Autoantibody biomarkers for the detection of serous ovarian cancer.
Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
[TBL] [Abstract][Full Text] [Related]
4. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
5. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
[TBL] [Abstract][Full Text] [Related]
6. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876
[TBL] [Abstract][Full Text] [Related]
7. A novel algorithm to improve specificity in ovarian cancer detection.
Arjomandi A; Delanoy ML; Walker RP; Binder SR
Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
[TBL] [Abstract][Full Text] [Related]
8. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.
Katchman BA; Barderas R; Alam R; Chowell D; Field MS; Esserman LJ; Wallstrom G; LaBaer J; Cramer DW; Hollingsworth MA; Anderson KS
Proteomics Clin Appl; 2016 Jul; 10(7):720-31. PubMed ID: 27121307
[TBL] [Abstract][Full Text] [Related]
9. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
[TBL] [Abstract][Full Text] [Related]
10. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
Sun H; Shi JX; Zhang HF; Xing MT; Li P; Dai LP; Luo CL; Wang X; Wang P; Ye H; Li LX; Zhang JY
Tumour Biol; 2017 Jun; 39(6):1010428317699132. PubMed ID: 28618923
[TBL] [Abstract][Full Text] [Related]
11. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
[TBL] [Abstract][Full Text] [Related]
12. Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients.
Tan Q; Wang D; Yang J; Xing P; Yang S; Li Y; Qin Y; He X; Liu Y; Zhou S; Duan H; Liang T; Wang H; Wang Y; Jiang S; Zhao F; Zhong Q; Zhou Y; Wang S; Dai J; Yao J; Wu D; Zhang Z; Sun Y; Han X; Yu X; Shi Y
Theranostics; 2020; 10(14):6399-6410. PubMed ID: 32483460
[No Abstract] [Full Text] [Related]
13. Comparison of candidate serologic markers for type I and type II ovarian cancer.
Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
[TBL] [Abstract][Full Text] [Related]
14. p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer.
Häfner N; Nicolaus K; Weiss S; Frey M; Diebolder H; Rengsberger M; Dürst M; Runnebaum IB
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1207-10. PubMed ID: 23576021
[TBL] [Abstract][Full Text] [Related]
15. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
[TBL] [Abstract][Full Text] [Related]
16. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
[No Abstract] [Full Text] [Related]
17. Serological autoantibody profiling of type 1 diabetes by protein arrays.
Miersch S; Bian X; Wallstrom G; Sibani S; Logvinenko T; Wasserfall CH; Schatz D; Atkinson M; Qiu J; LaBaer J
J Proteomics; 2013 Dec; 94():486-96. PubMed ID: 24148850
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
19. [Establishment and verification of detecting multiple biomarkers for ovarian cancer by suspension array technology].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li DR; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Oct; 51(10):765-772. PubMed ID: 27788745
[No Abstract] [Full Text] [Related]
20. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
Fortner RT; Damms-Machado A; Kaaks R
Gynecol Oncol; 2017 Nov; 147(2):465-480. PubMed ID: 28800944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
